2 Healthcare Stocks to Buy Before They Get Bought Out

Abivax: lead oral candidate obefazimod is in Phase 3 for moderately-to-severely active ulcerative colitis with top-line data expected in Q2; the UC market is estimated at $8.7B in 2026 rising to $14.3B by 2035. Abivax reported €589.7M (~$697M) cash at end-Q3 2025 (funding into Q4 2027), shares are down ~10% YTD but up >1,900% over the past year amid buyout rumors involving Eli Lilly and speculative interest from AstraZeneca. Nektar: rezpegaldesleukin showed >80% of patients maintained ≥75% skin clearance at 36 weeks in Phase 2b and may offer quarterly dosing; after a $460M raise it has >$700M liquidity (funding into 2027), shares are up ~77% YTD, and analysts’ targets of $123–$130 vs. current ~$74 imply material upside; potential acquirers cited include Sanofi, AbbVie, and Amgen.

Analysis

Large acquirers with immunology and inflammation franchises are the obvious strategic winners, but the more valuable second-order beneficiaries are CDMOs and oral small‑molecule manufacturing suppliers that can scale a rapid commercial rollout; acquirers will prefer targets that minimize biologics-capex and speed-to-patient, compressing premiums for strictly injectable platforms. Market pricing already embeds a non-trivial probability of a trade sale within 12 months, which means most future upside is M&A-dependent rather than de‑risked clinical-to-commercial translation — that shifts event-risk from science to negotiation/timing and counterparty balance sheets.

Tail risks are binary and asymmetric: a negative safety or regulatory signal can cascade into 50–80% downside inside days, while positive de‑risking typically unlocks a single-digit to low‑triple digit premium in a takeover scenario but only after protracted diligence (3–12 months). Payer/pricing dynamics are an underappreciated near‑term constraint — incumbents with high per‑patient prices create a ceiling for new entrants unless superior dosing, adherence, or cost-of-goods demonstrably change the lifetime‑value math.

From a positioning perspective, the prudent approach is event‑driven sizing with explicit hedges: isolate idiosyncratic readout/M&A exposure from biotech beta by pairing with a large‑cap immunology short or using volatility‑constrained option structures. Monitor short interest and implied vol term structure — a steep front‑month IV curve signals crowded event risk and makes spreads and collars a more efficient way to take asymmetric upside exposure.

Key Decisions for Investors

• Long-biotech event play: Allocate 1.0–1.5% NAV to ABVX (or similar small-cap target) with a 3‑month protective put 30% OTM sized to cap downside at ~35% of position cost; take profit at 100–150% if a public bid/term sheet is announced within 12 months. Rationale: caps tail risk while preserving M&A upside; downside if trial/regulatory fails is limited to the put cost plus retained equity.
• Volatility-defined upside on NKTR: Buy a 9‑month 1x2 call spread (buy ATM, sell 2x OTM) sized to 0.75% NAV to capture binary upside while financing premium with sold calls; close or roll at 50% of max gain. R/R: limited premium outlay with ~3–5x asymmetric upside if a takeover or accelerated commercial path materializes, limited loss to premium if not.
• Idiosyncratic-vs‑beta hedge: Pair long small‑cap biotech exposure (ABVX/NKTR combined <=2% NAV) with a 1% NAV short in a large immunology name (choose AMGN or ABBV) to hedge sector‑wide risk over a 6–12 month horizon. Rationale: isolates event-specific upside while reducing market correlation; expect reduced volatility but smaller absolute returns.
• Short post‑runup volatility: If either stock gaps up >25% on positive headlines without a clear term sheet, sell a 30–60 day covered call or iron‑condor to harvest elevated IV; size to 0.5–1% NAV and be prepared to unwind into firm bids. R/R: collect premium in high‑IV window; risk is assignment on a full‑takeout — size accordingly.